still, you have to innovate...make people want it more...I never bought one, but then again, not an extremist. you have to paint the picture of the average person using it for family fun, or on trips to Disney, etc, and show videos of more venues and events than races, etc. like I said, just never bought one because I didn't see the applications for "everyday life". would like the company to succeed, but need to i-n-n-o-v-a-t-e...imo.
to me, the support of a single institution speaks volumes as to the sustainability of XXII as a company...who throws $5.5MM down the drain?
this price level is unfamiliar to most here tho...seems very artificially established & manipulated, imo
the company has several products/technologies that hold promise if developed and sold effectively, imo. if there is news relating to the SALE of any or ALL of these technologies either to consumers of such products or to a significant buyer capable of selling these products in mass, i'm certain investors would like to know. but, enough of the "relationship-focused" releases that apparently serve no purpose other than being issued periodically in an effort to "inform"...not sure they meet the definition of "material events".
my bet is with FDA, no one else...to my knowledge, no other company is working on VLNs, and no other company has the patent portfolio for genetically altering nicotine that XXII has...can't ignore lung disease, lung cancer, COPD, mouth cancers, etc. forever...burden is HUGE on health care system...just my o. good luck.
thanks for opinion...had AINV, BX, etc. several years back - good divvy, appreciation; not so much today. wondered re: entry point now...good luck.
agreed...$1.13 was a bargain on perceived dilution; now, trending upward, passing $1.17...
amen...cash spurs growth, and the growth pays off for anyone taking advantage of perceived dilution if success follows...no-brainer, imo.
besides, the "vulture buyers" are likely going long, not short. the stock is down already, but things are beginning to take shape for a move upward on govt acceptance of "low-nico trend"...we shall see.
learn corporate finance, please...companies need CASH to grow...and no matter how much research XXII does, they cannot "genetically alter" the American dollar to produce more...
cash is king...a cash raise through an existing investor makes sense during a time of significant growth strategy execution, which I believe XXII is in...the hiring for FDA application and research was for me the catalyst to get things rolling. when the govt sees an opportunity to act to 1) attack a public health issue; and, 2) embrace positive change in an election year...things begin to move, imo.